Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View Item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

LOX-Mediated Collagen Crosslinking Is Responsible for Fibrosis-Enhanced Metastasis

Thumbnail
Publication Date
2013-03-15
ICR Author
Cox, Thomas
Bird, Demelza
Lang, Georgina
Author
Cox, TR
Bird, D
Baker, A-M
Barker, HE
Ho, MW-Y
Lang, G
Erler, JT
Type
Journal Article
Metadata
Show full item record
Abstract
Tumor metastasis is a highly complex, dynamic, and inefficient process involving multiple steps, yet it accounts for more than 90% of cancer-related deaths. Although it has long been known that fibrotic signals enhance tumor progression and metastasis, the underlying molecular mechanisms are still unclear. Identifying events involved in creating environments that promote metastatic colonization and growth are critical for the development of effective cancer therapies. Here, we show a critical role for lysyl oxidase (LOX) in establishing a milieu within fibrosing tissues that is favorable to growth of metastastic tumor cells. We show that LOX-dependent collagen crosslinking is involved in creating a growth-permissive fibrotic microenvironment capable of supporting metastatic growth by enhancing tumor cell persistence and survival. We show that therapeutic targeting of LOX abrogates not only the extent to which fibrosis manifests, but also prevents fibrosis-enhanced metastatic colonization. Finally, we show that the LOX-mediated collagen crosslinking directly increases tumor cell proliferation, enhancing metastatic colonization and growth manifesting in vivo as increased metastasis. This is the first time that crosslinking of collagen I has been shown to enhance metastatic growth. These findings provide an important link between ECM homeostasis, fibrosis, and cancer with important clinical implications for both the treatment of fibrotic disease and cancer. Cancer Res; 73(6); 1721-32. (c) 2012 AACR.
URL
https://repository.icr.ac.uk/handle/internal/2273
Open access location
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672851/
Collections
  • Other ICR Research
Version of record
10.1158/0008-5472.CAN-12-2233
Language
English
License start date
2013-03-15
Citation
CANCER RESEARCH, 2013, 73 pp. 1721 - 1732
Publisher
AMER ASSOC CANCER RESEARCH

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.